The BioPharm Brief: FDA Priority Review and Trispecific Antibodies Advance Precision Oncology

Mar 09, 08:16 PM
Headliner
Share
Subscribe

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research and clinical innovation. Today’s podcast highlights advances in targeted oncology therapies, from antibody‑drug conjugates, or ADCs, to next‑generation multispecific antibodies, and how these innovations are moving through regulatory and clinical pathways.

Share
Subscribe
Next
The BioPharm Brief: IL-23 Pathway Expansion Signals Next Wave of Immunology Lifecycle Development
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief